January 17, 2019
Geron Corporation reinforces in-house development team to boos phase 3 trial of imetelstat
Geron Corporation has included the first of several key leadership positions in rebuilding its in-house development team to boost a Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes by mid-year 2019.